课题基金 / 基金详情

Chemoprevention of Prostate Cancer, HDAC Inhibition, and DNA Methylation

Chemoprevention of Prostate Cancer, HDAC Inhibition, and DNA Methylation
前列腺癌的化学预防、HDAC 抑制和 DNA 甲基化
批准号:
8464015
负责人:
EMILY HO
金额:
$71.4万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-03-17 至 2013-08-31
关键词:
Aberrant DNA MethylationAccountingAcetylationAddressAdverse effectsAffectAmericanAnimal ModelAnimalsAntineoplastic AgentsApoptosisAttentionBase SequenceBiological MarkersBloodBroccoli - dietaryCancer EtiologyCancer PatientCarcinogensCell Cycle ArrestCell ProliferationCellsCessation of lifeChemopreventionChemopreventive AgentClinicalClinical TrialsCollaborationsColonoscopyColorectal CancerComplementConsumptionCultured CellsDNADNA MethylationDNA MethyltransferaseDNA Methyltransferase InhibitorDNA Modification MethylasesDNA RepairDNA StructureDevelopmentDiagnosisDietDietary InterventionDietary PhytochemicalDisease ProgressionDrug Metabolic DetoxicationEnzymesEpidemiologic StudiesEpigenetic ProcessEquilibriumEventFoodFoundationsFutureGene ExpressionGene SilencingGene TargetingGenesGenome StabilityGenomic InstabilityGlobal ChangeGoalsHealth Care CostsHealthcareHistone AcetylationHistone DeacetylaseHistone DeacetylationHistone H3Histone deacetylase inhibitionHistonesHumanHypermethylationIn VitroIncidenceIndole-3-CarbinolIndolesInduced MutationInjection of therapeutic agentIntakeInterventionIntervention StudiesIntervention TrialInvestigationIsothiocyanatesLeadLinkMalignant NeoplasmsMalignant neoplasm of lungMalignant neoplasm of prostateMeasurableMethodsMethylationModelingModificationMolecularMononuclearMorbidity - disease rateMutagensMutationNormal CellNutritionalOncogenesOutcomePathogenesisPathway interactionsPatientsPatternPharmaceutical PreparationsPhasePhytochemicalPlasmaPre-Clinical ModelPredispositionPrevention strategyPreventiveProcessProstateProstatic NeoplasmsProtein AcetylationProteinsPublic HealthQualifyingQuality of lifeRandomizedRecommendationReportingRepressionResearchRiskRisk FactorsRoleSulforaphaneSupplementationTestingTimeTissue SampleTissuesTumor Suppressor GenesUnited StatesUp-RegulationWorkbasecancer chemopreventioncancer preventioncancer recurrencecancer riskcancer therapycomparativecostcruciferous vegetablecyclin D2demethylationdouble-blind placebo controlled trialepigenetic markerepigenomefood consumptiongene repressionhigh riskhistone acetyltransferasehistone modificationimprovedin vivoinhibitor/antagonistinnovationinsightinterestlifestyle factorsliquid chromatography mass spectrometrymalemenmortalitynovelpreventpro-apoptotic proteinpromoterprostate cancer cellprostate cancer preventionprostate carcinogenesisprotective effectrandomized placebo controlled trialtranslational studytumortumor growthtumor progressionurinary

项目摘要

项目成果

EMILY HO的其他基金

相似基金

相关文献

中文摘要
翻译
前列腺癌是最常见的非皮肤癌,也是美国男性癌症死亡的第二大原因。启动和促进前列腺癌进展的确切病因尚不清楚,但表观遗传改变和饮食/生活方式因素已成为重要的促成因素。在前列腺癌期间,通过组蛋白去乙酰化和启动子甲基化等表观遗传模式的改变而使基因沉默是显而易见的。组蛋白脱乙酰酶(HDAC)或DNA甲基转移酶(DNMT)抑制剂等用于癌症预防和治疗的药物已引起人们的极大兴趣,并在癌症临床试验中显示出良好的前景。萝卜硫素(SFN)是十字花科蔬菜中发现的一种化合物,在动物模型中具有抑制肿瘤生长的作用,并能抑制前列腺中的HDAC活性。体外研究表明,异硫氰酸酯抑制前列腺癌细胞中的启动子甲基化和HDAC活性。基于这些发现,我们提出了以下中心假设:萝卜硫素在前列腺中起HDAC和DNMT1抑制剂的作用,导致组蛋白和蛋白质乙酰化和启动子去甲基化增强,并诱导细胞周期停滞/凋亡,从而预防癌症。这些研究的目的是确定植物化学物质通过表观遗传修饰改变基因表达的机制,从而防止前列腺癌的发展。具体地说,Aim 1测试了以表观遗传学改变为靶点的SFN和吲哚-3-甲醇(130)导致前列腺癌增殖减少的假设。目的2研究富含SFN和ISC的饮食对前列腺癌和前列腺癌的影响。工作假设是,这些化合物将抑制前列腺癌的发展,并将改变HDAC活性和靶向异常的DNA甲基化模式,从而抑制控制细胞凋亡和细胞增殖的基因。对于AIM 3中的翻译研究,使用一项随机、双盲、安慰剂对照试验来检验这一假设,即补充西兰花芽将增加前列腺中的SFN代谢物,抑制HDAC活性,并导致启动子去甲基化,从而增加组蛋白/非组蛋白的乙酰化和前列腺中的启动子去甲基化。这项建议的独特之处在于,我们将在细胞、动物中测试中心假说和相关机制,并通过对前列腺癌风险患者进行饮食干预试验。
英文摘要
Prostate cancer is the most frequently diagnosed non-cutaneous cancer, and is the second leading cause of cancer death in American men. The precise etiologic factors that initiate and enhance the progression of prostate cancer remains unknown, but epigenetic alterations and diet/lifestyle factors have come forth as significant contributing factors. During prostate cancer, silencing of genes via alterations in epigenetic patterns such as histone deacetylation and promoter methylation are apparent. Pharmacological agents that are histone deacetylase (HDAC) or DNA methyltransferase (DNMT) inhibitors for cancer prevention and therapy have gained significant interest and have shown promise in cancer clinical trials. We reported that sulforaphane (SFN), a compound found in cruciferous vegetables, suppresses tumor growth in animal models and inhibits HDAC activity in prostate. Studies in vitro showed that isothiocyanates inhibit both promoter methylation and HDAC activity in prostate cancer cells. Based on these findings we formulated the following CENTRAL HYPOTHESIS: Sulforaphane acts as an HDAC and DNMT1 inhibitor in the prostate, causing enhanced histone & protein acetylation and promoter demethylation, and induction of cell cycle arrest/apoptosis, leading to cancer prevention. The objective of these studies is to identify mechanisms by which phytochemicals alter gene expression via epigenetic modifications, and thereby prevent prostate cancer development. Specifically, Aim 1 tests the hypothesis that SFN and indole-3-carbinol (130) that target epigenetic alterations lead to a decrease in prostate cancer proliferation. Aim 2 investigates the effects of diets rich in SFN and ISC on epigenetic markers and cancer in the prostate in vivo. The working hypothesis is that these compounds will suppress prostate tumor development and will alter HDAC activity and target aberrant DNA methylation patterns leading to de-repression of genes controlling apoptosis and cell proliferation. For translational studies in Aim 3, use a randomized, double-blind, placebo-controlled trial to test the hypothesis that broccoli sprout supplementation will increase SFN metabolites in the prostate, inhibit HDAC activity, and cause promoter demethylation leading to an increase in histone/non-histone protein acetylation and promoter de-methylation in the prostate. The proposal is unique in that we will test the central hypothesis and associated mechanisms in cells, animals, and through a dietary intervention trial in patients at risk for prostate cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Integrated Health Sciences Facilities Core
  • 批准号:
    10383761
  • 项目类别:
  • 资助金额:
    $29.07万
  • 财政年份:
    2020
  • 负责人:
    EMILY HO
  • 依托单位:
Administrative Core
  • 批准号:
    10207637
  • 项目类别:
  • 资助金额:
    $31.83万
  • 财政年份:
    2020
  • 负责人:
    EMILY HO
  • 依托单位:
Pacific Northwest Center for Translational Environmental Health Research
  • 批准号:
    10383759
  • 项目类别:
  • 资助金额:
    $120.43万
  • 财政年份:
    2020
  • 负责人:
    EMILY HO
  • 依托单位:
Pacific Northwest Center for Translational Environmental Health Research
  • 批准号:
    10207636
  • 项目类别:
  • 资助金额:
    $120.43万
  • 财政年份:
    2020
  • 负责人:
    EMILY HO
  • 依托单位:
海外基金